- Aridis Pharmaceuticals Inc ARDS has entered into an exclusive, worldwide licensing agreement with AstraZeneca plc AZN to in-license the late-stage monoclonal antibody candidate, suvratoxumab for prevention of pneumonia.
- Suvratoxumab extends Aridis' pneumonia franchise by complementing the existing AR-301 Phase 3 pneumonia treatment program.
- Aridis will make an upfront payment to AstraZeneca of $11 million in cash and stock. AstraZeneca will also receive up to a further $115 million in milestone payments, in addition to tiered royalties on net sales.
- EU Commission's Innovative Medicines Initiatives has provided up to €25 million funding for the suvratoxumab Phase 3 trial.
- Price Action: ARDS shares are down 14.9% at $4.98 during the market session on the last check Monday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
